#  GHIT Fund Discovery Investment

# Target Research Platform

# RFP Intent to Apply Form

# Reference Number: GHIT-RFP-TRP-2025-001

|  |
| --- |
| **Please submit the Intent to Apply (ITA) form via Editorial Manager® for the Target Research Platform (**[**http://www.editorialmanager.com/ghitfund\_trp/)**](http://www.editorialmanager.com/ghitfund_trp/) **by 10:00am JST on November 28, 2024.** Please do not submit documents other than the ITA form to the GHIT Fund. Applicants who submit the ITA document will receive a confirmation e-mail. The GHIT Fund Management Team will then perform an initial partnership and scope eligibility assessment. **Only eligible applicants will be invited to submit a full proposal and will receive instructions to access the proposal template.**Should applicants have RFP-related questions, please send an e-mail to TRPResponse@ghitfund.org. Please also refer to the Frequently Asked Questions (FAQ) page on the GHIT website: <https://www.ghitfund.org/applyforfunding/investmentfaq/en>. |

Table of contents

[1. History of Applying for Funding to the GHIT Fund 2](#_Toc180592690)

[2. Project Title 2](#_Toc180592691)

[3. Project Focus 2](#_Toc180592692)

[**3.1 Award type (Please select only one)** 2](#_Toc180592693)

[**3.2 Intervention** 2](#_Toc180592694)

[4. Target Disease 2](#_Toc180592695)

[5. Partnership and Role/Responsibility 3](#_Toc180592696)

[6. Research/Project Summary 4](#_Toc180592697)

[**6.1 Goal of the Project (200-word limit)** 4](#_Toc180592698)

[**6.2 Project Overview (200-word limit)** 4](#_Toc180592699)

[**6.3 Japanese science and technology involved (200-word limit)** 4](#_Toc180592700)

[**6.4 Global Health Need and Impact (200-word limit)** 5](#_Toc180592701)

[7. Project Budget 5](#_Toc180592702)

[8. Compliance Checklist 5](#_Toc180592703)

[9. Agreement/Signature 6](#_Toc180592704)

# 1. History of Applying for Funding to the GHIT Fund

Please provide the project ID number for programs **related to this application,** if you applied for GHIT funding before.

*Insert Project ID Here*

*\*\*T201X-10X previous proposal decision (i.e. Awarded)\*\**

*\*\*Please specify if this new application is a continuation[[1]](#footnote-2) of a project previously funded by the GHIT Fund\*\**

# 2. Project Title

*Insert Project Title Here*

# 3. Project Focus

## **3.1 Award type (Please select only one)**

|  |  |  |
| --- | --- | --- |
| ☐ Standard TRP Award | [ ]  Strategic Innovation and Market Assessment Award | [ ]  R&D Accelerator Award |

## **3.2 Intervention**

|  |  |  |
| --- | --- | --- |
| ☐ Drug | [ ]  Vaccine | [ ]  Diagnostic |

# 4. Target Disease

|  |  |  |
| --- | --- | --- |
| ☐ Buruli Ulcer | ☐ Chagas Disease | ☐ Chikungunya |
| ☐ Dengue | ☐ Dracunculiasis (guinea-worm disease)  | ☐ Echinococcosis  |
| ☐ Foodborne Trematodiases  | ☐ Human African trypanosomiasis | ☐ Leishmaniasis |
| ☐ Leprosy | ☐ Lymphatic Filariasis | ☐ Malaria |
| ☐ Mycetoma | ☐ Chromoblastomycosis and other deep mycoses  | ☐ Noma  |
| ☐ Onchocerciasis | ☐ Rabies | ☐ Scabies |
| ☐ Schistosomiasis  | ☐ Soil-transmitted Helminthiases | ☐ Snakebite envenoming |
| ☐ Taeniasis-Cysticercosis | ☐ Trachoma | ☐ Tuberculosis |
| ☐ Yaws | ☐ Disease with Pandemic Potential[[2]](#footnote-3) |  |

# 5. Partnership and Role/Responsibility

The partnership consists of the following organizations (please add columns if your partnership consists of more than six organizations). Please note that the GHIT Fund requires each partnership to have at least one eligible Japanese organization and one eligible non-Japanese organization as partners in order to be considered eligible. For the Standard TRP Award, the project should primarily originate from or materially involve Japanese science and technology. Partnerships with other non-Japanese organizations that contribute to the expertise and potential success of the project are required.

|  |  |  |
| --- | --- | --- |
| Designated Development Partner[[3]](#footnote-4)Collaboration Partner 1 | Collaboration Partner 2 | Collaboration Partner 3 |
| Organization Name |  |  |  |
| Organization Type (e.g., PDP, pharma company, academic institution) |  |  |  |
| Organization Status | [ ]  Japanese [ ]  Non-JapanesePlease specify the country below | [ ]  Japanese [ ]  Non-JapanesePlease specify the country below | [ ]  Japanese [ ]  Non-JapanesePlease specify the country below |
| Organization Address and Phone Number  |  |  |  |
| Organization Webpage |  |  |  |
| Lead PI (name and job title) |  |  |  |
| Contact Details (e-mail and phone) |  |  |  |
| Role and Responsibility |  |  |  |

|  |  |  |
| --- | --- | --- |
| **Collaboration Partner 4** | **Collaboration Partner 5** | **Collaboration Partner 6** |
| Organization Name |  |  |  |
| Organization Type (e.g., PDP, pharma company, academic institution) |  |  |  |
| Organization Status | [ ]  Japanese [ ]  Non-Japanese Please specify the country below | [ ]  Japanese [ ]  Non-Japanese Please specify the country below | [ ]  Japanese [ ]  Non-Japanese Please specify the country below |
| Organization Address and Phone Number |  |  |  |
| Organization Webpage |  |  |  |
| Lead PI (name and job title) |  |  |  |
| Contact Details (e-mail and phone) |  |  |  |
| Role and Responsibility |  |  |  |

# 6. Research/Project Summary

## **6.1 Goal of the Project (200-word limit)**

Describe the ultimate goal of the project and provide an overview of the research, including the origin of the innovation/technology/research/know-how.

For example; What product/technology/know-how will be developed to address unmet medical needs? What landscape analysis will be conducted to address unmet and/or priority needs?

|  |
| --- |
|  |

## **6.2 Project Overview (200-word limit)**

Provide an overview of the **two-year project (six months for** the **Strategic Innovation and Market Assessment Award and the R&D Accelerator Award)** that you are applying for funding from the GHIT Fund, including milestones and activities, and the expected outcome/deliverables at the end of the project.

For example: How will the product/technology/know-how be developed? How will the landscape analysis be conducted? How will the translational science and capacity building be carried out?

|  |
| --- |
| *Such as What, Why, Who, When, How, How Much, Milestones, Activities, Deliverables, etc.* |

## **6.3 Japanese science and technology involved (200-word limit)**

Describe the role of Japanese science/technology/know-how in the project and its critical contribution to the development of the innovation/technology/research/know-how.

|  |
| --- |
|  |

## **6.4 Global Health Need and Impact (200-word limit)**

What makes this project unique in addressing global needs and making a significant impact

in the short or long term?

|  |
| --- |
|  |

# 7. Project Budget

Please provide the approximate amount of funding in Japanese Yen required to support the proposed project (**capital costs should be excluded**). Please provide the currency exchange rate used to calculate the total budget in Japanese Yen, if applicable.

|  |
| --- |
|  |

# 8. Compliance Checklist

Please answer the following questions regarding the Designated Development Partner, Collaboration Partner(s), and Principal Investigators who will be involved in the project proposed in this application (“Project”). Please mark ‘Yes’ or ‘No’ and provide explanations as needed. Please note that your answers in this section will be taken into account by the GHIT Fund as in its decision on your application.

|  |  |
| --- | --- |
| 1. Are there any pending or threatened civil, criminal, administrative, or regulatory proceedings, actions, suits, or investigations (either as a plaintiff or a defendant) that could have an effect on the Project?
 | [ ]  No[ ]  Yes – Please explain: |
| 1. Are sufficient measures in place to ensure that the project is implemented, controlled, managed, and monitored in compliance with all applicable ethical, legal, regulatory, and safety rules and requirements, including applicable international, national, local, industry, and institutional standards?
 | [ ]  No[ ]  Yes – Please explain: |
| 1. Are sufficient measures in place to prevent each of the following?
* Research Misconduct[[4]](#footnote-5)
* Misuse, misappropriation, or other inappropriate use of grants, donations, contributions, or subsidies[[5]](#footnote-6)
 | [ ]  No[ ]  Yes – Please explain: |
| 1. Please confirm that, to the best of their knowledge, the Designated Development Partner, Collaboration Partner(s), and/or Principal Investigator(s) have not, directly or indirectly supported or promoted, and will use reasonable efforts to ensure that they do not directly or indirectly support or promote, terrorist, criminal, or anti-social activities or related training, or money laundering.
 | [ ]  Confirm[ ]  Do not certify |
| 1. Please confirm that the Designated Development Partner, Collaboration Partner(s), and/or Principal Investigator(s) have never taken any action to directly or indirectly offer, pay, promise to pay, or authorize or approve the payment or giving of money, property, gifts, or anything else of value, directly or indirectly, to any government official in Japan or in any other jurisdiction or any official of any public international organization for the purpose of influence official action or securing an improper advantage.
 | [ ]  Confirm[ ]  Do not confirm |
| 1. Please read and acknowledge the “Award Administration and Conditions” described in the RFP.
 | [ ]  Acknowledge[ ]  Do not acknowledge |

# 9. Agreement/Signature

This Intent to Apply form is submitted by:

|  |  |
| --- | --- |
| Name:Title:Organization:Date: |  |
| AgreementWe hereby agree that the above information is accurate and true. We understand that any false information provided may result in the revocation of the proposal submitted.(Signature) |

[End of Document]

1. *“Continuation project” means a new application for an extended or continued project from a project previously funded by the GHIT Fund.* [↑](#footnote-ref-2)
2. *Proposals aimed at developing platform technologies for the rapid development of new pandemic products should provide a rationale for why the target disease is considered to have pandemic potential.* [↑](#footnote-ref-3)
3. *The Designated Development Partner will be the funding recipient and will be responsible for the performance of its Collaborating Partners. A representative of the Designated Development Partner will serve as the primary point of contact with the GHIT Fund and will be responsible for all discussions and negotiations with the GHIT Fund.* [↑](#footnote-ref-4)
4. *In the “Guidelines for Responding to Research Misconduct (Approved by the Ministry of Education, Culture, Sports, Science and Technology on August 26, 2014)”, each of the following acts is defined as specific research misconduct:*

*(1) Fabrication: making up data or research results, etc.*

*(2) Falsification: manipulating research materials, equipment, or procedures to alter data or results obtained from research activities*

*(3) Plagiarism: appropriating the ideas, analyses, analytical methods, data, research results, research paper(s), or words of other researchers without obtaining their permission of the researchers or giving appropriate credit* [↑](#footnote-ref-5)
5. *“Misuse” shall mean the use of such funds for purposes other than those originally intended or agreed upon, whether intentionally or through gross negligence.* [↑](#footnote-ref-6)